Abstract:Platinum complexes related to cisplatin, cis-[PtCl2(NH3)(2)], are successful anticancer drugs; however, other transition metal complexes offer potential for combating cisplatin resistance, decreasing side effects, and widening the spectrum of activity. Organometallic half-sandwich iridium (Ir-III) complexes [Ir(Cp-x)(XY)Cl](+/0) (Cp-x = biphenyltetramethylcyclopentadienyl and XY = phenanthroline (1), bipyridine (2), or phenylpyridine (3)) all hydrolyze rapidly, forming monofunctional G adducts on DNA with additional intercalation of the phenyl substituents on the Cp-x ring. In comparison, highly potent complex 4 (Cp-x = phenyltetramethylcyclopentadienyl and XY = N,N-dimethylphenylazopyridine) does not hydrolyze. All show higher potency toward A2780 human ovarian cancer cells compared to cisplatin, with 1, 3, and 4 also demonstrating higher potency in the National Cancer Institute (NCI) NCI-60 cell-line screen. Use of the NCI COMPARE algorithm (which predicts mechanisms of action (MoAs) for emerging anticancer compounds by correlating NCI-60 patterns of sensitivity) shows that the MoA of these IrIII complexes has no correlation to cisplatin (or oxaliplatin), with 3 and 4 emerging as particularly novel compounds. Those findings by COMPARE were experimentally probed by transmission electron microscopy (TEM) of A2780 cells exposed to 1, showing mitochondrial swelling and activation of apoptosis after 24 h. Significant changes in mitochondrial membrane polarization were detected by flow cytometry, and the potency of the complexes was enhanced ca. 5x by co-administration with a low concentration (5 mu M) of the gamma-glutamyl cysteine synthetase inhibitor L-buthionine sulfoximine (L-BSO). These studies reveal potential polypharmacology of organometallic Ir-III complexes, with MoA and cell selectivity governed by structural changes in the chelating ligands.

Cyclometalated Iridium(III) Complexes As Mitochondria-targeting Photosensitizers Against Cisplatin-resistant Cells.

Cyclometalated Iridium(III) Complexes as Mitochondria‐targeting Photosensitizers against Cisplatin‐resistant Cells <sup>†</sup>

Cyclometalated Iridium(iii) Complexes As Mitochondria-Targeted Anticancer Agents.

Mitochondria-targeted Neutral and Cationic Iridium(iii) Anticancer Complexes Chelating Simple Hybrid Sp2-N/sp3-n Donor Ligands.

Cyclometalated Ir(III) Complexes as Mitochondria-Targeted Photodynamic Anticancer Agents

Mitochondria-targeted Cyclometalated Iridium (III) Complexes: Dual Induction of A549 Cells Apoptosis and Autophagy.

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Fluorinated cyclometalated iridium(iii) complexes as mitochondria-targeted theranostic anticancer agents.

Mitochondria-targeted Phosphorescent Cyclometalated Iridium(iii) Complexes: Synthesis, Characterization, and Anticancer Properties

Cyclometalated iridium(iii) N-heterocyclic carbene complexes as potential mitochondrial anticancer and photodynamic agents.

Cyclometalated iridium(III) dithioformic acid complexes as mitochondria-targeted imaging and anticancer agents

Phosphorescent Iridium(iii)-Bis-n-heterocyclic Carbene Complexes As Mitochondria-Targeted Theranostic and Photodynamic Anticancer Agents.

Cyclometalated Iridium(iii)-Guanidinium Complexes As Mitochondria-Targeted Anticancer Agents.

Mitochondria-targeted Cyclometalated Iridium-Β-carboline Complexes As Potent Non-Small Cell Lung Cancer Therapeutic Agents

Synthesis, Photophysical and Anticancer Properties of Mitochondria-Targeted Phosphorescent Cyclometalated Iridium(iii) N-heterocyclic Carbene Complexes.

Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis

Anticancer Cyclometalated Iridium(III) Complexes with Planar Ligands: Mitochondrial DNA Damage and Metabolism Disturbance.

Dual Functions of Cyclometalated Iridium(III) Complexes: Anti-Metastasis and Lysosome-Damaged Photodynamic Therapy.

Cyclometalated Iridium(iii) Complexes Induce Mitochondria-Derived Paraptotic Cell Death and Inhibit Tumor Growth in Vivo.

Synthesis, Subcellular Localization and Anticancer Mechanism Studies of Unsymmetrical Iridium(III) Complexes

Cyclometalated Iridium(iii) Complexes for Mitochondria-Targeted Combined Chemo-Photodynamic Therapy.